Literature DB >> 23859118

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.

Xiaozhang Zheng1, Paul Bauer, Timm Baumeister, Alexandre J Buckmelter, Maureen Caligiuri, Karl H Clodfelter, Bingsong Han, Yen-Ching Ho, Nikolai Kley, Jian Lin, Dominic J Reynolds, Geeta Sharma, Chase C Smith, Zhongguo Wang, Peter S Dragovich, Janet Gunzner-Toste, Bianca M Liederer, Justin Ly, Thomas O'Brien, Angela Oh, Leslie Wang, Weiru Wang, Yang Xiao, Mark Zak, Guiling Zhao, Po-Wai Yuen, Kenneth W Bair.   

Abstract

Crystal structures of several urea- and thiourea-derived compounds in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein were utilized to design a potent amide-containing inhibitor bearing an aza-indole moiety (7, Nampt BC IC50 = 9.0 nM, A2780 cell proliferation IC50 = 10 nM). The Nampt-7 cocrystal structure was subsequently obtained and enabled the design of additional amide-containing inhibitors which incorporated various other fused 6,5-heterocyclic moieties and biaryl sulfone or sulfonamide motifs. Additional modifications of these molecules afforded many potent biaryl sulfone-containing Nampt inhibitors which also exhibited favorable in vitro ADME properties (microsomal and hepatocyte stability, MDCK permeability, plasma protein binding). An optimized compound (58) was a potent inhibitor of multiple cancer cell lines (IC50 <10 nM vs U251, HT1080, PC3, MiaPaCa2, and HCT116 lines), displayed acceptable mouse PK properties (F = 41%, CL = 52.4 mL/min/kg), and exhibited robust efficacy in a U251 mouse xenograft model.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23859118     DOI: 10.1021/jm4008664

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.

Authors:  Kayvan R Keshari; David M Wilson; Mark Van Criekinge; Renuka Sriram; Bertram L Koelsch; Zhen J Wang; Henry F VanBrocklin; Donna M Peehl; Tom O'Brien; Deepak Sampath; Richard A D Carano; John Kurhanewicz
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

2.  Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Authors:  Thomas O'Brien; Jason Oeh; Yang Xiao; Xiaorong Liang; Alexander Vanderbilt; Ann Qin; Lulu Yang; Leslie B Lee; Justin Ly; Ely Cosino; Jennifer A LaCap; Annie Ogasawara; Simon Williams; Michelle Nannini; Bianca M Liederer; Peter Jackson; Peter S Dragovich; Deepak Sampath
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Authors:  Bo Tan; Sucai Dong; Robert L Shepard; Lisa Kays; Kenneth D Roth; Sandaruwan Geeganage; Ming-Shang Kuo; Genshi Zhao
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

4.  Depletion of the central metabolite NAD leads to oncosis-mediated cell death.

Authors:  Christopher Del Nagro; Yang Xiao; Linda Rangell; Mike Reichelt; Thomas O'Brien
Journal:  J Biol Chem       Date:  2014-10-29       Impact factor: 5.157

Review 5.  New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.

Authors:  Anne Roulston; Gordon C Shore
Journal:  Mol Cell Oncol       Date:  2015-06-10

6.  Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells.

Authors:  Sanad Alonezi; Jonans Tusiimire; Jennifer Wallace; Mark J Dufton; John A Parkinson; Louise C Young; Carol J Clements; Jin-Kyu Park; Jong-Woon Jeon; Valerie A Ferro; David G Watson
Journal:  Metabolites       Date:  2017-04-14

7.  Metabolism of the Selective Matrix Metalloproteinase-9 Inhibitor (R)-ND-336.

Authors:  Charles Edwin Raja Gabriel; Trung T Nguyen; Emanuele Marco Gargano; Jed F Fisher; Mayland Chang; Shahriar Mobashery
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-06

Review 8.  Advances in NAD-Lowering Agents for Cancer Treatment.

Authors:  Moustafa S Ghanem; Fiammetta Monacelli; Alessio Nencioni
Journal:  Nutrients       Date:  2021-05-14       Impact factor: 5.717

9.  Structural basis for resistance to diverse classes of NAMPT inhibitors.

Authors:  Weiru Wang; Kristi Elkins; Angela Oh; Yen-Ching Ho; Jiansheng Wu; Hong Li; Yang Xiao; Mandy Kwong; Mary Coons; Bobby Brillantes; Eric Cheng; Lisa Crocker; Peter S Dragovich; Deepak Sampath; Xiaozhang Zheng; Kenneth W Bair; Thomas O'Brien; Lisa D Belmont
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

10.  Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.

Authors:  Yang Xiao; Mandy Kwong; Anneleen Daemen; Marcia Belvin; Xiaorong Liang; Georgia Hatzivassiliou; Thomas O'Brien
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.